Paying users zone. Data is hidden behind: .
Get 1-month access to Pfizer Inc. for $19.99, or
get full access to the entire website for at least 3 months from $49.99.
We accept:
This is a one-time payment. There is no automatic renewal.
Enterprise Value to FCFF (EV/FCFF)
Free Cash Flow to The Firm (FCFF)
Pfizer Inc., FCFF calculation
US$ in millions
Based on: 10-K (filing date: 2021-02-25), 10-K (filing date: 2020-02-27), 10-K (filing date: 2019-02-28), 10-K (filing date: 2018-02-22), 10-K (filing date: 2017-02-23).
1, 2 See details »
Item | Description | The company |
---|---|---|
FCFF | Free cash flow to the firm is the cash flow available to the Pfizer Inc.’s suppliers of capital after all operating expenses have been paid and necessary investments in working and fixed capital have been made. | Pfizer Inc.’s FCFF decreased from 2018 to 2019 and from 2019 to 2020. |
Interest Paid, Net of Tax
Pfizer Inc., interest paid, net of tax calculation
US$ in millions
Based on: 10-K (filing date: 2021-02-25), 10-K (filing date: 2020-02-27), 10-K (filing date: 2019-02-28), 10-K (filing date: 2018-02-22), 10-K (filing date: 2017-02-23).
2 2020 Calculation
Cash paid during the period for interest, tax = Cash paid during the period for interest × EITR
= × =
3 2020 Calculation
Capitalized interest, tax = Capitalized interest × EITR
= × =
Enterprise Value to FCFF Ratio, Current
Pfizer Inc., current EV/FCFF calculation, comparison to benchmarks
Selected Financial Data (US$ in millions) | |
Enterprise value (EV) | |
Free cash flow to the firm (FCFF) | |
Valuation Ratio | |
EV/FCFF | |
Benchmarks | |
EV/FCFF, Competitors1 | |
Abbott Laboratories | |
AbbVie Inc. | |
Amgen Inc. | |
Bristol-Myers Squibb Co. | |
Eli Lilly & Co. | |
Gilead Sciences Inc. | |
Illumina Inc. | |
Johnson & Johnson | |
Merck & Co. Inc. | |
Regeneron Pharmaceuticals Inc. | |
Vertex Pharmaceuticals Inc. | |
Zoetis Inc. | |
EV/FCFF, Sector | |
Pharmaceuticals & Biotechnology | |
EV/FCFF, Industry | |
Health Care |
Based on: 10-K (filing date: 2021-02-25).
1 Click competitor name to see calculations.
If the company EV/FCFF is lower then the EV/FCFF of benchmark then company is relatively undervalued.
Otherwise, if the company EV/FCFF is higher then the EV/FCFF of benchmark then company is relatively overvalued.
Enterprise Value to FCFF Ratio, Historical
Pfizer Inc., historical EV/FCFF calculation, comparison to benchmarks
Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Enterprise value (EV)1 | ||||||
Free cash flow to the firm (FCFF)2 | ||||||
Valuation Ratio | ||||||
EV/FCFF3 | ||||||
Benchmarks | ||||||
EV/FCFF, Competitors4 | ||||||
Abbott Laboratories | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Illumina Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
Zoetis Inc. | ||||||
EV/FCFF, Sector | ||||||
Pharmaceuticals & Biotechnology | ||||||
EV/FCFF, Industry | ||||||
Health Care |
Based on: 10-K (filing date: 2021-02-25), 10-K (filing date: 2020-02-27), 10-K (filing date: 2019-02-28), 10-K (filing date: 2018-02-22), 10-K (filing date: 2017-02-23).
3 2020 Calculation
EV/FCFF = EV ÷ FCFF
= ÷ =
4 Click competitor name to see calculations.
Valuation ratio | Description | The company |
---|---|---|
EV/FCFF | Enterprise value to free cash flow to the firm is whole company valuation indicator. | Pfizer Inc.’s EV/FCFF ratio increased from 2018 to 2019 and from 2019 to 2020. |